Lung Diseases	Asthma and allergy	Cardiovascular Risk and COPD
Pathogenesis of COPD	Lung cancer	Airway and Therapeutic Devices
CO-Morbidities in COPD	Management of COPD	Pulmonary diseases-Treatment and therapies
COPD Exacerbations	Diagnostic Evaluation of COPD	Pediatric Pulmonary, Critical care and Sleep
Epidemiology of COPD	Pulmonary Hypertension	Environmental and Occupational lung Disease
COPD Therapeutics	Lung Transplantation	Self-Management and Prevention of COPD

 

Lung Diseases

Lung Diseases are the absolute most basic medical condition in the world. Smoking, infections, and genetics are main cause for lung diseases. The lungs are a piece of mechanical assembly, growing and loosening up a great many occasions every day to get oxygen and remove carbon dioxide. Lung infection can result from part of the lung.

• Asthma.
• Cystic Fibrosis (CF)/ Bronchiectasis.
• Lung cancer
• Pleural effusion
• Pneumonia

Lung Transplantation

A lung transplant expels an individual's diseased lung and replaces it with a healthy one. The healthy lung originates from a benefactor who has died. Lung transplants are utilized for individuals who are probably going to die from lung diseases within 1 to 2 years. Their conditions are severe to different medications, for example, drugs or breathing gadgets, no longer work. Lung transplants regularly are utilized to treat individuals who have serious COPD, Cystic fibrosis, Idiopathic pulmonary fibrosis, Alpha-1 antitrypsin inadequacy and pulmonary hypertension.

• Single-lung
• Double-lung
• Heart–lung

Respiratory Infections

Respiratory Tract infection (RTI) includes various infectious diseases of the respiratory tract. An infection of this type classified as upper respiratory tract infection (URI or URTI) or a lower respiratory tract infection (LRI or LRTI).

Upper respiratory tract infections include pharyngitis, laryngitis, tonsillitis, and certain types of influenza, sinusitis, otitis media and the common cold. Lower respiratory tract infections include bronchitis and pneumonia

• Upper respiratory tract infection
• Lower respiratory tract infection

Asthma and allergy

Allergy occurs when the immune system in an individual responds to allergens which are substances in condition that don't cause issues for many people. This response prompts irritation (redness and swelling) that causes unfavorably susceptible conditions, which can influence different parts  of the body, for example, hypersensitive rhinitis, skin inflammation or urticaria, hypersensitivity and asthma.

Individuals with asthma experience a narrowing of the airway routes in the lungs, which obstructs the stream of air into and out of the lungs.

• Dust mites.
• Be short of breath
• Breathe quickly
• Feel your chest get tight

Pathogenesis of COPD

Pathologic changes in chronic obstructive pulmonary disease (COPD) happen in the large (central) airway routes, the little (peripheral) bronchioles, and the lung parenchyma. Most instances of COPD are the consequence of introduction to noxious stimuli,, regularly tobacco smoke. The normal inflammatory response is enhanced in people inclined to COPD advancement. Increased quantities of activated polymorphonuclear leukocytes and macrophages discharge elastases in a way that can't be neutralized viably by antiproteases, bringing about lung destruction.

• Chronic bronchitis
• Emphysema
• Refractory asthma

CO-Morbidities in COPD

Comorbidities like heart disease, hypertension, osteoporosis, diabetes mellitus and psychological disorders are generally reported in patients with chronic obstructive pulmonary disease (COPD). Tobacco smoking is a hazard factor for huge numbers of these comorbidities just as for COPD, making it hard to draw conclusions about the connection among COPD and these comorbidities.

COPD Exacerbations

Exacerbations drive wellbeing status and contribute to disease enhancement and exacerbation prevention is a key objective for treatment of COPD. Most of COPD exacerbations are activated by respiratory viral and bacterial infections.

• Type 1 exacerbations
• Type 2 exacerbations
• Type 3 exacerbations

Epidemiology of COPD

Chronic obstructive pulmonary disease (COPD) is a main source of world-wide mortality and disability. On average ∼5– 15% of adults in industrialized nations have COPD characterized by spirometry. In 1990, COPD was determined as at the twelfth position worldwide reason for consolidated mortality and disability but it is expected to be the fifth cause by 2020

COPD has an chronic long-lasting course with irreversible decrease of forced expiratory volume in one second (FEV1), increasing nearness of dyspnoea and other respiratory manifestations, and dynamic decay of wellbeing status. After analysis the 10-yr survival rate is ∼50% with more than 33% of patients dying because of respiratory inadequacy.

Management of COPD

COPD management plan includes

(1) evaluate and screen disease

(2) reduce risk factors

(3) manage stable COPD

(4) manage exacerbations.

Prevention of COPD

COPD can be prevented by avoiding tobacco exposure and toxic fumes. Vaccination against viral influenza and Streptococcus pneumoniae is prescribed.

• Avoid exposure
• Help fight for clean air

Lung cancer

Lung cancer is a condition where cells multiply in the lungs uncontrollably. This causes the development of tumors that decrease an individual's capacity to breathe. This development can spread beyond the lung by the process of metastasis into close-by tissue or different parts of the body.

• Adenocarcinoma
• Squamous cell cancer
• Large cell carcinoma
• Undifferentiated non-small cell lung cancer

Interstitial Lung Disease

Interstitial Lung Disease is a general class that includes a wide range of lung conditions. All interstitial lung diseases influence the interstitium, a part of the lungs' anatomic structure.

• Interstitial pneumonia
• Idiopathic pulmonary fibrosis
• Nonspecific interstitial pneumonitis
• Hypersensitivity pneumonitis

Pulmonary Hypertension

Pulmonary hypertension is a kind of hypertension that influences the supply routes in your lungs and the right side of your heart.

• pulmonary arterial hypertension
• pulmonary hypertension due to left heart disease
• pulmonary hypertension due to lung disease and/or chronic hypoxia.
• pulmonary hypertension due to blood clots in the lungs

Cardiovascular Risk and COPD

Individuals with chronic obstructive pulmonary disease(COPD) have a higher inclination and mortality from cardiovascular diseases, and diminishing cardiovascular mortality is the target region for decreasing mortality in individuals with COPD.

• Smoking
• Lack of exercise
• Obesity
• High LDL or low HDL cholesterol levels

Therapeutic Devices & Evaluation

The common lung function tests are Spirometry, Chest X-ray, CT scan, Arterial blood gas analysis, Ventilation perfusion scan, Endobronchial Ultrasound (EBUS), Exhaled Nitric Oxide Test, Methacholine Challenge Test and many more.

Pulmonary diseases-Treatment and therapies

Pulmonary, Critical care and Sleep

Pulmonary, Critical care and Sleep includes various diseases related pulmonary diseases, sleep disorders and its critical care.

• Pulmonary arterial hypertension (PAH)
• Pulmonary hypertension due to left-sided heart disease

Occupational & Environmental lung Disease

Occupational & Environmental lung diseases are group of diseases caused by the inhalation of dust, chemicals, or proteins. The severity of the disease is identified with the material inhaled and the intensity of exposure.

Some of the Occupational Lung diseases are Asthma, Bronchiolitis Obliterans, COPD, Hypersensitivity Pneumonitis, Lung Cancer, Mesothelioma, Pneumoconiosis.

Some of the Environmental lung diseases caused by Arsenic, Asbestos, BCME, Beryllium, Cadmium, Chromium, Coal dust, Diesel exhaust, Indium lung, Nickel, Silica and Tobacco smoke etc

 

1^st round of Abstract Submission Deadline:  February 28, 2020
2nd round of Abstract Submission Deadline: March 28, 2020
Final round of Abstract submission Dates:  July 28, 2020

Link: https://copd.conferenceseries.com/abstract-submission.php

1st round of Registration Deadline: February 28, 2020
2nd round of Registration Deadline: March 28, 2020
Final round of Registration: August 18, 2020

Link: https://copd.conferenceseries.com/registration.php

 

AUTHOR ELIGIBILITY:

• Individuals may submit up to two regular abstracts as the first author.
• Individuals may submit an unlimited number of Trials in Progress abstracts.
• Individuals may serve as a co-author on an unlimited number of abstracts.

• All types of Pulmonologists, Thoracic Surgeon’s, Medicinal, Health research are eligible for submission.
• Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
• Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. 
• Interim analysis of a prospective randomized clinical trial will be considered if it is performed as planned in the original protocol and is statistically valid.
• Abstracts of clinically-related subjects should be combined into a single abstract. 

Note: Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.

Submission Requirements

Provide your full name, academic degree(s), institution, address, and email address and recent photograph. You will receive all future correspondence from us regarding the status of your abstract. 

The selected abstracts will be published in Conference Proceedings.

Important Dates:

Early Bird Discount Registration Offer: On/Before March 28, 2020

Early Bird Abstract Submission Date: March 28, 2020

Speaker Presentations Sessions and Time limits:

Keynote Speech 40-45 Minutes,

Workshop/Symposium 60 Minutes

Plenary Speech 20-25 Minutes, 

Poster Presentation 10-15 Minutes

 

 

Global Market research on COPD

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach

a value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA

fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

North America leads the global market for asthma &COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment.

Major COPD Research Associations around Asia Pacific

COPD Patient Organization of Vietnam

COPD Patients Club Kyrgyzstan

COPD Club of Northern Thailand

Asian Pacific Society of Respirology

Chinese COPD Patient Education Organziation

Major COPD Research Associations around Globe

Alpha-1 Foundation

American Association for Respiratory Care

American College of Chest Physicians

American College of Emergency Physicians

American College of Physicians

American Lung Association

Canadian Lung Association (CLA)

COPD Foundation

Target Audience:

• Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments

• COPD Students, Scientists, Faculty

• Medical Colleges

• COPD Associations and Societies

• Business Entrepreneurs, Pharmaceutical companies

Universities Associated with COPD 2017

Major Universities on COPD Research

Kumamoto University, Japan

Tokyo National Hospital, Japan

KindaiUniversity, Japan

Okayama University, Japan

Medi7 Bentleigh, Australia

Macquarie University, Australia

Australian national university, Australia

Charles Darwin University Casoria Australia

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Iqbal Chest Centre, Bangladesh

Imperial College London, United Kingdom

Linnaeus University, Sweden

University Of California Los Angeles, United States

Columbia University Medical Center, United States

Harvard University, United States

 

Top few companies in this global market:

AstraZeneca

GlaxoSmithKline

F. Hoffmann-La Roche

Novartis and Merck

Abbott

Amgen

Actavis

Boehringer Ingelheim

Cipla

Glenmark

Pfizer

Ranbaxy

Sunovion

Vectura

Global COPD & Asthma Devices Market, By Product

Inhalers

Nebulizers

Inhalers accounted for the major market and is expected to continue its dominance till 2020

Global COPD & Asthma Devices Market, By Geography

North America

Europe

Asia-Pacific

LAMEA

LAMEA region would exhibit the highest CAGR of 4.9% during 2017-2020